Cargando…
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
BACKGROUND: In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer (TNBC). METHODS: Gene expression and clinical–pathological data were evaluated in five independent cohorts, including three randomised clinic...
Autores principales: | Prat, A, Lluch, A, Albanell, J, Barry, W T, Fan, C, Chacón, J I, Parker, J S, Calvo, L, Plazaola, A, Arcusa, A, Seguí-Palmer, M A, Burgues, O, Ribelles, N, Rodriguez-Lescure, A, Guerrero, A, Ruiz-Borrego, M, Munarriz, B, López, J A, Adamo, B, Cheang, M C U, Li, Y, Hu, Z, Gulley, M L, Vidal, M J, Pitcher, B N, Liu, M C, Citron, M L, Ellis, M J, Mardis, E, Vickery, T, Hudis, C A, Winer, E P, Carey, L A, Caballero, R, Carrasco, E, Martín, M, Perou, C M, Alba, E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200088/ https://www.ncbi.nlm.nih.gov/pubmed/25101563 http://dx.doi.org/10.1038/bjc.2014.444 |
Ejemplares similares
-
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
por: Alba, E, et al.
Publicado: (2014) -
Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain
por: Segui, M. A., et al.
Publicado: (2019) -
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
por: Prat, A., et al.
Publicado: (2012) -
Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain
por: Font, R, et al.
Publicado: (2012) -
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
por: Martín, Miguel, et al.
Publicado: (2013)